Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Applied Therapeutics ( (APLT) ) has shared an update.
On December 11, 2025, Applied Therapeutics announced a merger agreement with Cycle Group Holdings Limited, where Cycle will acquire all outstanding shares of Applied Therapeutics. The transaction involves a tender offer for $0.088 per share in cash plus a contingent value right (CVR) for potential additional payments based on certain milestones. The merger is expected to close in the first quarter of 2026, subject to customary conditions. The Applied Board of Directors unanimously approved the agreement, viewing it as the best strategic option for the company and its shareholders.
The most recent analyst rating on (APLT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.
Spark’s Take on APLT Stock
According to Spark, TipRanks’ AI Analyst, APLT is a Underperform.
Applied Therapeutics is in the early stages of revenue generation, but significant challenges in achieving profitability and sustaining operations through negative cash flow pose risks. The technical analysis shows downward momentum, and valuation metrics reflect its current unprofitability. Focus remains on operational improvements and expense management to navigate financial instability.
To see Spark’s full report on APLT stock, click here.
More about Applied Therapeutics
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates targeting rare diseases. Their lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor aimed at treating CNS rare metabolic diseases such as Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD), and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG).
Average Trading Volume: 13,646,312
Technical Sentiment Signal: Sell
Current Market Cap: $31.75M
Find detailed analytics on APLT stock on TipRanks’ Stock Analysis page.